# Who Responds in the Real World

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/who-responds-in-the-real-world

> Tirzepatide nearly doubled the share reaching 15% weight loss in a year. The same study found outcomes differing by race, where 64 randomized trials found none. The disagreement is the finding.

## Key points

- 42.6% vs 21.6% reached ≥15% weight loss in year one, tirzepatide against semaglutide.
- Real-world outcomes differed by race; 64 randomized trials found no such difference.
- Trials supply the drug free, escalate on protocol and chase follow-up, which equalizes access.
- A gap that appears only outside trials is a gap in treatment, not in patients.

A large propensity-matched real-world study found tirzepatide nearly **doubled** the proportion of people reaching 15% weight loss in a year, at 42.6% against 21.6%.[1] It also found something that contradicts a review we cover elsewhere: outcomes differed by race and ethnicity, when 64 randomized trials had found no such difference.[2] Both findings are real, and the reason they disagree is the important part.

## The drug comparison

Among matched patients, 42.6% reached at least 15% weight loss in year one on tirzepatide against 21.6% on semaglutide, with faster monthly weight-loss velocity (2.54% against 2.18%). Tirzepatide was also associated with a lower prevalence of gastrointestinal and systemic adverse events.[1]

> The adverse event comparison came from what the authors describe as AI-enabled curation of records, which is not the same thing as adjudicated safety data from a trial. Treat the efficacy comparison as the stronger half of this study and the tolerability comparison as suggestive.

## The finding that contradicts the trials

In this cohort, women were over-represented among high responders. So were White patients. Black and Hispanic patients were over-represented among those achieving minimal weight loss, under 5%.[1]

That is not what the randomized evidence shows. A systematic review of 64 trials found no significant heterogeneity by race across nine trials and 25,229 patients, or by ethnicity across seven trials and 8,328 patients (covered in [who loses more weight on a GLP-1](https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1)).[2] The sex difference appears in both.

> A review of 64 randomized trials found no significant heterogeneity by race across 25,229 patients.

## Why the settings disagree

A randomized trial does things that ordinary care does not. It supplies the drug at no cost. It escalates the dose on a fixed protocol. It follows people up relentlessly, chases missed appointments, and replaces medication that goes astray. In doing all that, it *equalizes* the things that differ most between patients outside a trial: access, affordability, continuity and titration.

Strip those supports away and the differences reappear. Someone who cannot afford an uninterrupted supply, or whose prior authorization is denied, or who never reaches the maintenance dose because refills lapse, will show a smaller weight change, and none of that is physiology.

- **Cost and coverage differ systematically**, and this market is largely cash-pay. Our [price dispersion piece](https://glpwatchdog.org/research/how-much-glp1-prices-actually-vary) shows how much the same drug varies between sellers.
- **Dose escalation requires continuity.** Reaching the effective dose takes months of uninterrupted supply, and interruption resets progress.
- **Interruption is common** in a market defined by shortages and subscription lapses, and it does not fall evenly.
- **Trials selected participants** who could attend, comply and persist, which is its own filter.

> **A gap that appears only outside trials is a gap in treatment, not in patients.** When a drug performs equally across groups under controlled conditions and unequally in ordinary care, the difference lies in the conditions. Reading this as a biological difference would be both unsupported by the randomized evidence and a way of blaming people for an access problem.

## What to take from it

There are two separate lessons here, and they should not be merged. On drug choice, this is real-world evidence that tirzepatide outperforms semaglutide on weight, consistent with the randomized picture in our [timeline article](https://glpwatchdog.org/research/tirzepatide-results-timeline), though this is an observational cohort, and matching can adjust only for what was measured.

On response variation, the useful reading is that continuity of supply is a large part of what produces a good outcome. If cost, coverage or a seller’s reliability is going to interrupt your access, solve that before starting, because the gap between trials and ordinary care suggests it matters a great deal.

## Frequently asked questions

### Is tirzepatide better than semaglutide in the real world?

On weight, this study says yes. Among propensity-matched patients, 42.6% reached at least 15% weight loss in a year on tirzepatide against 21.6% on semaglutide, with faster monthly weight loss and, on a weaker measure, fewer adverse events.

### Do GLP-1 drugs work less well for some racial groups?

Not according to randomized trials, which found no significant difference by race across nine trials and 25,229 patients. This real-world cohort did find differences, and the most likely explanation is what trials equalize and ordinary care does not: cost, continuity of supply and dose escalation.

### Why would a trial and real-world data disagree?

Because a trial supplies the drug free, escalates on protocol and chases every missed appointment. Those supports remove the differences that matter most outside a trial. A gap appearing only in ordinary care points at the conditions of care rather than at physiology.

### Does continuity matter that much?

Reaching an effective dose takes months of uninterrupted supply, and interruption resets progress. In a market defined by shortages, cash-pay pricing and subscription lapses, it is common, and you can plan around it before starting.

### Do women respond better?

Women were over-represented among high responders here, and randomized trials also found greater percentage weight loss in women.

## References

1. Venkatakrishnan AJ, Murugadoss K, Soundararajan V, et al. Weight-loss dynamics with tirzepatide versus semaglutide. PNAS Nexus. 2026. PMID: 42311474. https://pubmed.ncbi.nlm.nih.gov/42311474/
2. Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. JAMA Internal Medicine. 2026. PMID: 41770554. https://pubmed.ncbi.nlm.nih.gov/41770554/

---

Cite as: GLP Watchdog, Ruth Calder, "Who Responds in the Real World", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/who-responds-in-the-real-world

Canonical HTML page: https://glpwatchdog.org/research/who-responds-in-the-real-world

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
